Lexaria Bioscience (LEXX) Revenue Growth (1y) (2018 - 2026)
Lexaria Bioscience (LEXX) Revenue Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.45% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 16.73% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 59.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 29.63% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 66.86% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -99.97% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 296.11% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 16.50% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | -88.51% |
| Aug 31, 2025 | 107.14% |
| May 31, 2025 | 107.14% |
| Feb 28, 2025 | 20.00% |
| Nov 30, 2024 | 21.58% |
| Aug 31, 2024 | 173.25% |
| May 31, 2024 | 8.10% |
| Feb 29, 2024 | 624.09% |
| Nov 30, 2023 | 54.78% |
| Aug 31, 2023 | -72.34% |
| May 31, 2023 | -22.07% |
| Feb 28, 2023 | -34.67% |
| Nov 30, 2022 | 604.14% |
| Aug 31, 2022 | 258.31% |
| May 31, 2022 | -51.13% |
| Feb 28, 2022 | -84.04% |
| Nov 30, 2021 | -95.31% |
| Aug 31, 2021 | -51.52% |
| May 31, 2021 | 460.24% |
| Feb 28, 2021 | 411.35% |